Stockreport

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients [Yahoo! Finance]

Bio-Path Holdings, Inc.  (BPTH) 
Last bio-path holdings, inc. earnings: 11/14 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: biopathholdings.com
PDF Reallocates Resources to Metabolic Program and Discontinues Enrollment in Phase 1 Study of BP1002 to Treat Relapsed/Refractory Lymphoma and Relapsed/Refractory Chronic [Read more]